Home – Neurimmune

Transforming the wisdom of life

into promising drug candidates

Neurimmune’s scientists discovered with the Reverse Translational Medicine technology the anti-ATTR antibody Cliramitug (formerly ALXN2220, NI006) for ATTR cardiomyopathy, the anti-SOD1 antibody AP-101 for ALS and the anti-NogoA antibody NG004 for spinal cord injury. These programs are currently evaluated in clinical trials.

Neurimmune pipeline

Decoding immune memories of life

to develop therapeutic antibodies

By using Reverse Translational Medicine™ technology, Neurimmune’s scientists and researchers translate genetic information of lymphocyte transcripts from elderly human donors into therapeutic antibodies. Evolutionarily optimized and wisely elected antibodies with preferred activities combine high affinity with target selectivity, excellent pharmacodynamics and low immunogenicity.

RTM™ Technology Platform

Scientific publications

View all

N Engl J Med - 2023

Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

Sci Transl Med. - 2018

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis

Nature - 2016

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

News

View all

05.12.2025 | Press Release

AL-S Pharma today presented its Phase 2 clinical study results on AP-101 at the 36th International Symposium on ALS/MND in San Diego.

04.12.2025 | Press Release

Neurimmune today announced that it has expanded on its ATTR-CM collaboration with Alexion, AstraZeneca Rare Disease by entering into a collaboration and license agreement to develop NI009 for the treatment of AL amyloidosis.

14.10.2025 | Company News

Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug for transthyretin amyloid cardiomyopathy in patients who were previously enrolled in the proof-of-concept study NI006-101.

Driven by the passion for life

to help patients around the world

Roger M Nitsch, MD

CEO

View details

Christoph Hock, MD

CMO

View details

Jan Grimm, PhD

CSO

View details